167 related articles for article (PubMed ID: 33753620)
1. Determining PD-L1 expression in head and neck squamous cell carcinoma using immunohistochemistry.
Mishra PS; Sidhu A; Dwivedi G; Mulajker DS; Awasthi S
Indian J Cancer; 2022; 59(4):474-479. PubMed ID: 33753620
[TBL] [Abstract][Full Text] [Related]
2. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
[TBL] [Abstract][Full Text] [Related]
3. Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
Vainer G; Huang L; Emancipator K; Nuti S
PLoS One; 2023; 18(6):e0285764. PubMed ID: 37267266
[TBL] [Abstract][Full Text] [Related]
4. The clinicopathological significance of PD-L1 expression assessed by the combined positive score (CPS) in head and neck squamous cell carcinoma.
Wusiman D; Guo L; Huang Z; Li Z; Liu S; Ying J; Li W; An C
Pathol Res Pract; 2022 Aug; 236():153934. PubMed ID: 35691098
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical study of Programmed Cell Death Ligand 1 (PDL1) expression by combined positive score using 22C3 clone in head and neck squamous cell carcinomas, its correlation with clinicopathological features and outcome.
Gangadhar P; Ilanthodi S; Shetty R; Shenoy KK; Philipose TR
J Oral Maxillofac Pathol; 2024; 28(1):29-36. PubMed ID: 38800420
[TBL] [Abstract][Full Text] [Related]
7. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in fine-needle aspiration cell blocks of head and neck squamous-cell carcinoma and its cytohistological concordance.
Lou SSK; Ruff H; MacDonald S; Smith SM; Cheung CC
Diagn Cytopathol; 2024 Mar; 52(3):163-170. PubMed ID: 38095142
[TBL] [Abstract][Full Text] [Related]
9. Comparison of PD-L1 IHC 22C3 PharmDx Combined Positive Score (CPS) in Primary Versus Metastatic Nodal Squamous Cell Carcinomas of the Head and Neck: Is There a Significant Difference?
Surucu A; Hou T; Kuhar M; Durm G; Mesa H
Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):550-554. PubMed ID: 37358840
[TBL] [Abstract][Full Text] [Related]
10. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC).
de Ruiter EJ; Mulder FJ; Koomen BM; Speel EJ; van den Hout MFCM; de Roest RH; Bloemena E; Devriese LA; Willems SM
Mod Pathol; 2021 Jun; 34(6):1125-1132. PubMed ID: 32759978
[TBL] [Abstract][Full Text] [Related]
11. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
12. The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer.
Yu SL; Hsiao YJ; Cooper WA; Choi YL; Avilés-Salas A; Chou TY; Coudry R; Raskin GA; Fox SB; Huang CC; Jeon YK; Ko YH; Ku WH; Kwon GY; Leslie C; Lin MC; Lou PJ; Scapulatempo-Neto C; Mendoza Ramírez S; Savelov N; Shim HS; Lara Torres CO; Cunha IW; Zavalishina L; Chen YM
Pathology; 2023 Feb; 55(1):19-30. PubMed ID: 36319485
[TBL] [Abstract][Full Text] [Related]
13. Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma.
Hirshoren N; Al-Kharouf I; Weinberger JM; Eliashar R; Popovtzer A; Knaanie A; Fellig Y; Neuman T; Meir K; Maly A; Vainer GW
Oncology; 2021; 99(7):464-470. PubMed ID: 33789303
[TBL] [Abstract][Full Text] [Related]
14. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of PD-L1 expression in head and neck squamous cell carcinoma: An institutional experience from India.
Kala PS; Thapliyal N; Pant B; Sharma N; Pandey HS
Pathol Res Pract; 2024 Feb; 254():155133. PubMed ID: 38306860
[TBL] [Abstract][Full Text] [Related]
16. High interobserver and intraobserver reproducibility among pathologists assessing PD-L1 CPS across multiple indications.
Nuti S; Zhang Y; Zerrouki N; Roach C; Bänfer G; Kumar GL; Manna E; Diezko R; Kersch K; Rüschoff J; Jasani B
Histopathology; 2022 Dec; 81(6):732-741. PubMed ID: 35993150
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
[TBL] [Abstract][Full Text] [Related]
18. Inter-assay reliability of programmed cell death-ligand 1 in head and neck squamous cell carcinoma.
Hempenius MA; Bisheshar SK; Slagter-Menkema L; van der Kamp MF; Halmos GB; Doff JJ; Willems SM; van der Vegt B
Oral Oncol; 2022 Nov; 134():106086. PubMed ID: 35995004
[TBL] [Abstract][Full Text] [Related]
19. Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types.
Wang C; Hahn E; Slodkowska E; Eskander A; Enepekides D; Higgins K; Vesprini D; Liu SK; Downes MR; Xu B
Hum Pathol; 2018 Dec; 82():131-139. PubMed ID: 30075156
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity.
Karabajakian A; Bouaoud J; Michon L; Kamal M; Crozes C; Zrounba P; Auclair-Perossier J; Gadot N; Attignon V; Le Tourneau C; Benzerdjeb N; Fayette J; Saintigny P
Oral Oncol; 2021 Aug; 119():105368. PubMed ID: 34111704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
